PBMs have long claimed to reduce drug costs and enhance healthcare value, but their complex business practices have instead increased medication costs through hidden fees, rebate schemes, and anti-competitive pricing. Operating as expensive intermediaries, they have effectively extracted billions from the healthcare system while failing to deliver on their promise of cost control and value addition to patients and employers.

The success of open markets in reducing costs across industries like retail (Amazon), transportation (Uber, Lyft, Tesla), and travel suggests a similar approach could transform healthcare. While transparent PBMs represent a step in the right direction, there’s potential for even more significant improvements through market-based solutions that could help achieve better outcomes at lower costs.

Mark Cuban, cofounder of Cost Plus Drugs, believes his transparent pricing model could be his most impactful venture yet. Pramod John, CEO of VIVIO, will introduce VIVIO’s PrecisionCare One platform which offers an open market, data-driven alternative to the PBM model.

Mark and Pramod explore how open market solutions are revolutionizing healthcare purchasing. Discover how self-insured companies can fulfill their fiduciary duties while enhancing corporate wellness programs, improving benefits, reducing costs, and delivering better health outcomes for their employees.

Webinar Discussion Points:

• Right drug, right person, right price, the right outcome—the core mission
• The power of open markets
• Proof in action: Cost Plus Drugs transformed generics pricing, VIVIO revolutionized
  specialty drugs
• Why PBM contract gibberish like rebate and discount guarantees lead to higher costs
• Current PBM practices create legal risks for employers’ fiduciary duties
• Replacing PBMs with transparent, open market solutions is possible today

FOR
Employers
Benefits consultants
Employee benefits professionals
Media
Any interested person